Research in the January 2023 issue of the Journal of the National Comprehensive Cancer Network finds that immunotherapy from PD-1 inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high colorectal cancer.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe